Recombinant ACE2 has been previously in development as a therapeutic for vascular diseases [28] and more recently has been in clinical trial as a treatment for COVID-19 [29], and, in all cases, the drug was well tolerated without drug-related adverse events [30, 31]. Here, ACE2 is linked to COVID-19.